ZY H7

Drug Profile

ZY H7

Alternative Names: ZYH7

Latest Information Update: 07 Jul 2016

Price : $50

At a glance

  • Originator Zydus Cadila
  • Class Antihyperlipidaemics
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dyslipidaemias; Hypertriglyceridaemia
  • No development reported Metabolic disorders

Most Recent Events

  • 31 May 2015 ZY H7 is still in phase II trials for Dyslipidaemias (presumably including Hypertriglyceridaemia) in India
  • 28 Feb 2014 Phase-II development is ongoing in India
  • 04 Jul 2012 Zydus Cadila completes a phase II trial in Dyslipidaemias in India (NCT01539616)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top